ESMO 2023 | eNRGy: zenocutuzumab in NRG1 fusion-positive pancreatic ductal adenocarcinoma

Alison Schram, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses results from the Phase II eNRGy trial (NCT02912949), which is assessing the safety, tolerability and anti-tumor activity of the bispecific antibody zenocutuzumab in patients with NRG1 fusion-positive solid tumors. Here, she discusses the encouraging results in patients with pancreatic ductal adenocarcinoma. The data shows a promising overall response rate, and the median duration of response (mDoR) was 9.1 months. 84% of patients had a greater than 50% decline in CA 19-9 from baseline. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.